TR 354 Mouse Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
DIMETHOXANE
NTP Experiment-Test: 05038-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/05/94
Route: GAVAGE Time: 09:04:29
Facility: Battelle Columbus Laboratory
Chemical CAS #: 828-00-2
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 7 5 9
Dead 7 9 7
Survivors
Terminal Sacrifice 36 35 34
Missing 1
Animals Examined Microscopically 50 49 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (14) (50)
Gallbladder (44) (6) (45)
Intestine Large, Cecum (46) (10) (48)
Leiomyoma 1 (2%)
Intestine Small, Duodenum (46) (8) (45)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (48) (13) (45)
Liver (50) (19) (50)
Choriocarcinoma, Metastatic, Ovary 1 (2%)
Hemangioma 1 (5%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 2 (4%) 1 (2%)
Hepatocellular Carcinoma, Multiple 2 (11%)
Hepatocellular Adenoma 7 (14%) 3 (16%) 4 (8%)
Histiocytic Sarcoma 1 (2%)
Ito Cell Tumor NOS 1 (2%)
Mesentery (41) (11) (49)
Pancreas (49) (15) (49)
Salivary Glands (48) (13) (49)
Stomach, Forestomach (49) (48) (48)
Squamous Cell Papilloma 3 (6%) 3 (6%) 1 (2%)
Stomach, Glandular (49) (12) (48)
Adenoma 1 (8%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (14) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (14) (50)
Capsule, Adenoma 1 (2%)
Adrenal Gland, Medulla (49) (14) (50)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Pituitary Gland (47) (19) (45)
Pars Distalis, Adenoma 6 (13%) 4 (21%) 6 (13%)
Thyroid Gland (50) (14) (47)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (21) (50)
Cystadenoma 1 (5%) 1 (2%)
Granulosa-Theca Tumor Benign 1 (2%)
Mixed Tumor Benign 1 (2%)
Yolk Sac Carcinoma 1 (2%)
Uterus (50) (43) (50)
Histiocytic Sarcoma 1 (2%)
Polyp Stromal 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (14) (50)
Hemangiosarcoma 1 (2%)
Femoral, Hemangiosarcoma 1 (2%)
Femoral, Histiocytic Sarcoma 1 (2%)
Lymph Node (50) (16) (50)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinal, Histiocytic Sarcoma 1 (2%)
Mediastinal, Osteosarcoma, Metastatic, Skin 1 (6%)
Mediastinal, Mesenteric, Fibrosarcoma,
Metastatic, Skin 1 (2%)
Lymph Node, Mandibular (48) (13) (49)
Page 3
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Spleen (50) (23) (50)
Hemangiosarcoma 1 (2%) 1 (4%)
Histiocytic Sarcoma 1 (2%)
Thymus (31) (9) (31)
Histiocytic Sarcoma 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (44) (10) (40)
Adenocarcinoma 1 (2%) 2 (5%)
Adenoma 1 (3%)
Skin (50) (14) (49)
Basosquamous Tumor Malignant 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 3 (21%) 2 (4%)
Subcutaneous Tissue, Osteosarcoma,
Metastatic, Bone 1 (7%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (14) (50)
Osteosarcoma 1 (7%)
Skeletal Muscle (50) (13) (50)
Fibrosarcoma, Metastatic, Skin 1 (8%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (14) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (14) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 1 (7%) 3 (6%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%)
Basosquamous Tumor Malignant, Metastatic,
Skin 1 (2%)
Choriocarcinoma, Metastatic, Ovary 1 (2%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (7%)
Mediastinum, Alveolar/Bronchiolar Carcinoma 1 (2%)
Nose (50) (14) (50)
Trachea (49) (14) (50)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (48) (11) (50)
Adenoma 2 (4%) 1 (2%)
Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (14) (50)
Urinary Bladder (49) (12) (49)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(49) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant 2 (4%)
Lymphoma Malignant Histiocytic 10 (20%) 3 (6%) 5 (10%)
Lymphoma Malignant Lymphocytic 4 (8%) 6 (12%) 5 (10%)
Lymphoma Malignant Mixed 3 (6%) 6 (12%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 32 26 33
Total Primary Neoplasms 50 34 53
Total Animals with Benign Neoplasms 20 13 17
Total Benign Neoplasms 26 15 23
Total Animals with Malignant Neoplasms 18 18 22
Total Malignant Neoplasms 24 19 29
Total Animals with Metastatic Neoplasms 2 4
Total Metastatic Neoplasm 4 5
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 6 11 9
Dead 11 10 12
Survivors
Terminal Sacrifice 33 27 29
Wrong Sex 2
Animals Examined Microscopically 50 48 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (49) (21) (50)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (5%)
Squamous Cell Papilloma 1 (5%)
Intestine Small, Ileum (44) (16) (44)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Intestine Small, Jejunum (47) (19) (44)
Liver (49) (28) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Cholangiocarcinoma 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (4%)
Hemangiosarcoma 1 (4%) 1 (2%)
Hemangiosarcoma, Multiple 3 (6%) 1 (2%)
Hepatocellular Carcinoma 9 (18%) 8 (29%) 6 (12%)
Hepatocellular Carcinoma, Multiple 2 (7%)
Hepatocellular Adenoma 6 (12%) 5 (18%) 11 (22%)
Hepatocellular Adenoma, Multiple 1 (2%) 2 (4%)
Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Mesentery (41) (19) (48)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (5%)
Page 7
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Hemangiosarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Pancreas (48) (20) (49)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Stomach, Forestomach (47) (47) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 3 (6%) 7 (14%)
Squamous Cell Papilloma, Multiple 1 (2%)
Stomach, Glandular (47) (20) (50)
Adenocarcinoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (21) (50)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Carcinosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (21) (50)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Adenoma 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Capsule, Adenoma 5 (10%) 3 (6%)
Adrenal Gland, Medulla (50) (21) (50)
Pheochromocytoma Benign 2 (4%)
Islets, Pancreatic (48) (19) (49)
Adenoma 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Pituitary Gland (46) (20) (41)
Pars Distalis, Carcinoma 1 (5%)
Thyroid Gland (49) (22) (50)
Follicular Cell, Adenoma 1 (2%) 1 (5%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (45) (20) (49)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Epididymis (50) (21) (47)
Fibrosarcoma, Metastatic, Skin 1 (5%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Prostate (48) (21) (49)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Seminal Vesicle (43) (20) (46)
Fibrosarcoma, Metastatic, Skin 1 (5%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (21) (50)
Femoral, Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (50) (24) (49)
Axillary, Fibrosarcoma, Metastatic, Skin 1 (4%)
Bronchial, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Inguinal, Fibrosarcoma, Metastatic, Skin 1 (4%)
Mediastinal, Sarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Lymph Node, Mandibular (48) (20) (49)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Spleen (49) (26) (50)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (4%)
Hemangioma 2 (4%)
Hemangiosarcoma 1 (2%) 1 (4%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Thymus (27) (12) (24)
Sarcoma, Metastatic, Uncertain Primary Site 1 (4%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (33) (49)
Subcutaneous Tissue, Fibroma 2 (4%) 4 (8%)
Subcutaneous Tissue, Fibrosarcoma 8 (16%) 9 (27%) 5 (10%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 2 (4%) 1 (3%)
Subcutaneous Tissue, Hemangiosarcoma 1 (3%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (49) (21) (49)
Fibrosarcoma, Metastatic, Skin 3 (14%)
Diaphragm, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (25) (50)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Alveolar/Bronchiolar Adenoma 8 (16%) 2 (8%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (8%) 4 (8%)
Carcinosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 3 (12%) 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (48) (25) (48)
Adenoma 2 (4%) 2 (8%) 2 (4%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (23) (50)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Adenoma 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 2 (4%)
Fibrosarcoma, Metastatic, Skin 1 (4%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Urethra (23) (15) (29)
Transitional Epithelium, Carcinoma 1 (7%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(48) *(50)
Lymphoma Malignant 1 (2%)
Lymphoma Malignant Histiocytic 4 (8%) 1 (2%) 3 (6%)
Lymphoma Malignant Lymphocytic 2 (4%) 1 (2%)
Lymphoma Malignant Mixed 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:29
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 31 37
Total Primary Neoplasms 68 43 68
Total Animals with Benign Neoplasms 18 13 26
Total Benign Neoplasms 32 14 41
Total Animals with Malignant Neoplasms 29 26 18
Total Malignant Neoplasms 36 29 27
Total Animals with Metastatic Neoplasms 6 7 3
Total Metastatic Neoplasm 18 16 22
Total Animals with Malignant Neoplasms 3
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 71376-71376/71376
--multipart-boundary--